AZN vs NVO

AstraZeneca PLC and Novo Nordisk A/S, both Healthcare

AstraZeneca PLC is the larger company at $271B against $191B. Over the past year AZN returned +13% against +1.5% for NVO.

AstraZeneca PLC and Novo Nordisk A/Scompared on valuation, return and Ryufin’s Smart Score
FigureAZNNVO
Last close$166$47.19
Market cap$271B$191B
Trailing P/Elower is cheaper for the same earnings, not automatically better27.4n/a
1-year return+13%+1.5%
5-year return+61%+13%
Ryufin Smart Scoresector-relative, 1–109/109/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

AstraZeneca PLC

Revenue of $31B in H2 2025, net income $4.9B.

AZN overviewrevenue and segmentsvaluation

Novo Nordisk A/S

NVO overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or read the correlation.